Action Observation and Motor Imagery Therapy in Parkinson's Disease
- Disease/Condition
- Parkinson's Disease
- Drug/Device/Intervention
- Action observation and motor imagery therapy for rehabilitation
- Study type
- Interventional
- Intervention type
- other
- Primary sponsor
- Karamanoğlu Mehmetbey University
- Location
- Karaman, Turkey
- Phase
- N/A
- Start date
- Nov 30, 2023
- End date
- Dec 01, 2024
- Enrollment
- 54 participants
The difference in the scores of the Berg Balance Scale between pre- and post-rehabilitation assessments,The difference in the scores of the Unified Parkinson's Disease Rating Scale (UPDRS) between pre- and post-rehabilitation assessments,The difference in the scores of the Timed Up and Go Test (TUG) between pre- and post-rehabilitation assessments,The difference in the scores of the Five Times Sit to Stand Test between pre- and post-rehabilitation assessments
In recent years, motor imagery (MI) and action observation (AO) therapy strategies have been
 used in rehabilitation programs to increase motor learning in Parkinson's disease (PD).
 Visuomotor training strategies such as AO and MI therapy rely on the activity of the mirror
 neuron system to facilitate motor re-learning. Mirror neurons are activated during the
 performance of goal-directed actions, also when observing the same action and visualizing the
 action in the mind.
 
 The aim of this clinical trial is to test whether the application of AO and MI treatment in
 PD in addition to conventional rehabilitation programs has an additional effect on Balance,
 Functional Status and Quality of Life.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06154356
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06154356 through Pure Global AI's free database. This phase not specified trial is sponsored by Karamanoğlu Mehmetbey University and is currently Not yet recruiting. The study focuses on Parkinson's Disease. Target enrollment is 54 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.